Preclinical Efficacy of IMM-BCP-01, a Highly Active Patient-Derived Anti-SARS-CoV-2 Antibody Cocktail

Article activity feed

1. 

   ScreenIT

   Oct 22, 2021

   SciScore for 10.1101/2021.10.18.464900: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Ethics	Field Sample Permit: Animal studies: All animal studies described in the manuscript were carried out under Institutional Animal Care and Use Committee (IACUC)-approved protocols at the respective institutions (BU and MRIGlobal) and where appropriate were reviewed and approved by Animal Care and Use Review Office of USAMRDC (ACURO). IACUC: Animal studies: All animal studies described in the manuscript were carried out under Institutional Animal Care and Use Committee (IACUC)-approved protocols at the respective institutions (BU and MRIGlobal) and where appropriate were reviewed and approved by Animal Care and Use Review Office of USAMRDC (ACURO).
   Sex as a biological variable	not detected.
   Randomiz…

   SciScore for 10.1101/2021.10.18.464900: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Ethics	Field Sample Permit: Animal studies: All animal studies described in the manuscript were carried out under Institutional Animal Care and Use Committee (IACUC)-approved protocols at the respective institutions (BU and MRIGlobal) and where appropriate were reviewed and approved by Animal Care and Use Review Office of USAMRDC (ACURO). IACUC: Animal studies: All animal studies described in the manuscript were carried out under Institutional Animal Care and Use Committee (IACUC)-approved protocols at the respective institutions (BU and MRIGlobal) and where appropriate were reviewed and approved by Animal Care and Use Review Office of USAMRDC (ACURO).
   Sex as a biological variable	not detected.
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.
   Cell Line Authentication	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   The antibody/RVP mixture was pre-incubated for 1 hour in a 37□C incubator containing 5% CO2.	antibody/RVP suggested: None
   Plates were blocked with endotoxin-free 2% gelatin solution (Sigma) and incubated with anti-Spike antibodies of interest for 1 hour at +4°C.	anti-Spike suggested: None
   Cells with deposited complement components were stained with anti-C4 antisera (Complement Technology) and a secondary anti-goat-HRP antibody (SouthernBiotech).	anti-C4 antisera (Complement Technology) suggested: None anti-goat-HRP suggested: None
   Plates were washed (3x) and subsequently probed for ACE2 binding with anti-ACE2 antibody.	anti-ACE2 suggested: None
   Experimental Models: Cell Lines
   Sentences	Resources
   Cells: Reporter virus particles (RVP’s) were purchased from Integral Molecular, ACE2-293T cells (Integral Molecular; Cat #C-HA102) were cultured in DMEM containing 10% FBS, 10mM HEPES, and 0.5 g/mL Puromycin.	ACE2-293T suggested: None
   Vero E6 cells (BEI resources, NIAID, NIH: VERO C1008 (E6), African green monkey kidney, Working Cell Bank NR-596) were maintained in humidified incubators at 37°C and 5% CO2 in DMEM high glucose with GlutaMAX and sodium pyruvate (Gibco™, cat #10569) and 10% certified US-origin heat-inactivated fetal bovine serum (Gibco™, cat #10082).	Vero E6 suggested: RRID:CVCL_XD71)
   The mutant library was arrayed in 384-well microplates and transiently transfected into HEK293T cells.	HEK293T suggested: CCLV Cat# CCLV-RIE 1018, RRID:CVCL_0063)
   100 μL of THP-1 cells at 2.5e5 cells per mL are then added to wells containing bead-antigen-antibody mixture.	THP-1 suggested: CLS Cat# 300356/p804_THP-1, RRID:CVCL_0006)
   CHO-S1 target cells (Promega Cat #CS3195A06) and Jurkat NFAT-Luc effector cells were mixed at 2:1 (E:T) ratio.	Jurkat suggested: TKG Cat# TKG 0209, RRID:CVCL_0065)
   Software and Algorithms
   Sentences	Resources
   Plate is then run on Attune NXT for acquisition and FCS Files are analyzed using FlowJo Software.	FlowJo suggested: (FlowJo, RRID:SCR_008520)
   The half maximal inhibitory concentrations (IC50) were calculated using GraphPad Prism 8.	GraphPad Prism suggested: (GraphPad Prism, RRID:SCR_002798)

   ---

   Results from OddPub: Thank you for sharing your data.

   ---

   Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

   ---

   Results from TrialIdentifier: No clinical trial numbers were referenced.

   ---

   Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

   ---

   Results from JetFighter: We did not find any issues relating to colormaps.

   ---

   Results from rtransparent:

   • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
   • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
   • No protocol registration statement was detected.

   ---

   Results from scite Reference Check: We found no unreliable references.

   ---

   Read the original source
2. 

   Version published to 10.1101/2021.10.18.464900 on bioRxiv

   Oct 19, 2021